| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | -6,5 M € | +86.9% | -49,5 M € | -5.4% | -47,0 M € | -797.5% | -5,2 M € | +14.0% | -6,1 M € | -137.3% | -2,6 M € | -7.5% | -2,4 M € | |
| EBITDA | -6,5 M € | +86.9% | -49,5 M € | -5.4% | -47,0 M € | -750.4% | -5,5 M € | +13.4% | -6,4 M € | -124.1% | -2,8 M € | -7.6% | -2,6 M € | |
| Operating profit | -6,5 M € | +86.9% | -49,5 M € | -5.4% | -47,0 M € | -624.9% | -6,5 M € | +11.6% | -7,3 M € | -92.9% | -3,8 M € | -5.6% | -3,6 M € | |
| Profit/loss | -12,0 M € | +80.3% | -60,6 M € | -30.1% | -46,6 M € | -644.5% | -6,3 M € | +12.0% | -7,1 M € | -91.5% | -3,7 M € | -6.7% | -3,5 M € | |
| Equity | -129,9 M € | -10.1% | -118,0 M € | -105.5% | -57,4 M € | -1025.1% | 6,2 M € | -3.9% | 6,5 M € | -15.2% | 7,6 M € | -32.8% | 11,3 M € | |
| Total assets | 607,5 k € | -62.8% | 1,6 M € | +138.5% | 684,7 k € | -91.7% | 8,2 M € | +0.1% | 8,2 M € | -9.3% | 9,0 M € | -26.8% | 12,3 M € | |
| Cash | — | — | — | 6,5 M € | +12.9% | 5,7 M € | +19.1% | 4,8 M € | -35.5% | 7,5 M € | ||||
| Debts | 116,4 M € | -2.7% | 119,6 M € | +105.9% | 58,1 M € | +2801.3% | 2,0 M € | +15.2% | 1,7 M € | +112.2% | 818,7 k € | -19.6% | 1,0 M € | |
Public limited company · Wavre · incorporated on 19/12/2017
Public limited company loss-making in the latest fiscal year. Cash position rising (+12.9%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
SYNDESI THERAPEUTICS is a Public limited company incorporated in 2017. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Wavre.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette